---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-22-000051"
form_type: "8-K/A"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:48:30.484527+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Halozyme completes Antares acquisition for $5.60/sh; total consideration ~$1.0457B

## Summary
- Aggregate purchase consideration $1,045.7M; each Antares share converted into $5.60 cash.
- Pro forma combined 2021 revenue $627.3M, net income $286.2M; basic EPS $2.04.
- Pro forma Q1 2022 revenue $158.8M, net income $36.2M; basic EPS $0.26.
- Financing includes $250M term loan and $350M revolving credit facility from BofA.
- Nonrecurring acquisition-related costs of $40.5M expensed in pro forma statements.

## SEC filing metadata
- accession: 0001159036-22-000051
- form_type: 8-K/A
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000051/0001159036-22-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903622000051/halo-20220524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-22-000051
- JSON: https://secwatch.observer/filing/0001159036-22-000051.json
- Plain text: https://secwatch.observer/filing/0001159036-22-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.